Block price target raised to $90 from $75 at Bernstein
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Key Points Novo Nordisk and Regeneron have encountered challenges recently. Both companies are significantly trailing the market this year. These healthcare leaders still could perform well in the long run. 10 stocks we like better than Novo Nordisk › Even with all the volatility and the flirting with bear-market territory, the S&P 500 index is well in the green this year, up about 8% since early January. Some stocks haven't been so lucky, though. Novo Nordisk (NYSE: NVO) and Regeneron Pharmaceuticals (NASDAQ: REGN), two leading drugmakers, have underperformed for most of the year, significantly lagging the broader market. These healthcare giants are facing some headwinds, but does that mean investors should steer clear of them? Let's find out. 1. Novo Nordisk Novo Nordisk has been facing several challenges that predate this year. It encountered a clinical setback for what Wall Street thought was a promising weight management candidate. Furthermore, the company's financial results, although strong when compared to its similarly sized peers, were not seen as sufficient because it's held to a higher standard. These challenges have led to a terrible performance this year. Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a steal right now. The company has made several moves that should allow it to recover. Novo Nordisk's pipeline, especially in diabetes and weight management, remains one of the strongest in the industry. It recently initiated a phase 3 study for amycretin -- its next-generation GLP-1 medicine -- in both subcutaneous and oral formulations. It requested regulatory approval in the U.S. for an oral version of semaglutide, its well-known medicine marketed as Wegovy for weight loss and as Ozempic for diabetes management. Novo Nordisk has also penned several licensing deals that have expanded its pipeline in weight management. The company should launch at least one new medicine in its core therapeutic area within the next few years. Financial results should remain strong as Ozempic and Wegovy continue driving solid revenue growth. Considering the stock's sell-off over the past years, shares now look more than reasonably valued relative to Novo Nordisk's growth potential. Their forward price-to-earnings ratio of 16.9 is in line with the healthcare industry's average of 16.5 as of this writing. However, Novo Nordisk typically grows its revenue and earnings faster than its peers. That makes its stock attractive at current levels, based on its growth potential. 2. Regeneron Pharmaceuticals Regeneron is facing biosimilar competition for Eylea, a medicine for wet age-related macular degeneration that was once one of its biggest growth drivers. Sales of the medicine have dropped, dragging total revenue down with them. That's the most important reason why Regeneron's shares are down by 19% since the year started. However, the stock is still attractive. The biotech might go through a period of its top line declining, but it can still recover. Here are three reasons why. First, the company's newer, higher-dose (HD) formulation of Eylea is taking market share away from its previous version. HD Eylea is performing well and will grow even faster once it earns some label expansions. Second, Regeneron has a deep pipeline that's expected to yield new brand approvals. Earlier this month, it earned the green light for Lynozyfic, a cancer medicine, in the U.S. One of its more promising candidates is a gene therapy for one type of genetic deafness, which is showing incredible potential in clinical trials. Regeneron should move beyond Eylea thanks to newer approvals. Third, the company's most important product, Dupixent, an eczema treatment, is performing exceptionally well. The medicine has earned important label expansions in recent years, including in treating chronic obstructive pulmonary disease (COPD) and a rare skin condition called bullous pemphigoid. Dupixent will maintain its upward growth trajectory for a while. Here's one more reason to invest in Regeneron: The company is committed to returning capital to shareholders. It recently initiated a dividend and has a robust share-buyback program in place. The stock might be moving in the wrong direction right now, but those willing to hold onto it for five years or more could see superior returns over the long run. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Are Losing to the S&P 500 This Year was originally published by The Motley Fool Connectez-vous pour accéder à votre portefeuille
Yahoo
an hour ago
- Yahoo
3 Vanguard ETFs That Can Turn $500 per Month Into Over $1 Million
Key Points These three Vanguard ETFs have delivered exceptional returns since inception. Investing $500 per month while obtaining those historical returns would grow to $1 million in 24 years or less. However, there's no guarantee that these ETFs will generate such lofty returns over the next several decades. 10 stocks we like better than Vanguard S&P 500 ETF › What's the most important secret to becoming a successful chef? Knowing the right ingredients to use. I think this is also the secret to becoming a successful investor. The primary ingredients of investing are capital, time, and solid investment assets. How much money you can make depends on how much money you have to invest, how much time you have, and which assets you invest in. Exchange-traded funds (ETFs) rank among the best investment assets for long-term investors. And Vanguard offers some of the most attractive ETFs around. Here are three Vanguard ETFs that can turn $500 per month into over $1 million. 1. Vanguard S&P 500 ETF I think the easiest choice to amass a $1 million fortune is the Vanguard S&P 500 ETF (NYSEMKT: VOO). As its name indicates, this ETF aims to track the performance of the S&P 500 (SNPINDEX: ^GSPC), which includes the 500 largest U.S. companies. Over the long run, the S&P 500 has delivered an average annual total return (with dividends reinvested) of around 10%. If you invested $500 per month and achieved that return, you'd have nearly $1.09 million at the end of 30 years. At the end of 40 years, your portfolio would be worth more than $2.9 million. These amounts, by the way, assume that you invest in a tax-advantaged account, such as an individual retirement account (IRA), and don't pull any money out along the way. Granted, the Vanguard S&P 500 ETF hasn't been around for 30 or 40 years. Vanguard launched the fund in September 2010. Since its inception, the ETF has delivered an average annual total return of 13.6%. If you were able to make this higher return, your $500 per month would grow to over $1 million in only 24 years. After 30 years, you'd amass a fortune of over $2.2 million. There's no guarantee that the Vanguard S&P 500 ETF will generate an average return of 13.6% -- or even 10%. However, those returns are certainly possible. One of the advantages of the S&P 500 is that it regularly replaces laggards with rising stars. It's also weighted by market cap, which means the stocks that grow the most affect the index's performance the most. 2. Vanguard S&P 500 Growth ETF If the S&P 500 can achieve 10% returns over the long term, it stands to reason that the fastest-growing stocks in the index could deliver even greater returns. That's the premise behind the Vanguard S&P 500 Growth ETF (NYSEMKT: VOOG). This Vanguard ETF focuses only on growth stocks in the S&P 500. It currently owns 212 stocks, instead of the 505 stocks in the Vanguard S&P 500 ETF (this number is greater than 500 because some companies have multiple classes of shares). Since its inception in September 2010, the Vanguard S&P 500 Growth ETF has generated an average annual return of 16.4%. If you were able to obtain this return and invested $500 per month, your money would grow to a little over $4 million in 30 years. You'd have $1 million within 22 years. Can the Vanguard S&P 500 Growth ETF continue to deliver such a lofty return over the next several decades? Probably not. However, I think this fund could nonetheless turn $500 per month into over $1 million for those who begin investing at an early age. 3. Vanguard Russell 1000 Growth ETF Let's expand our horizons somewhat. What if, instead of limiting ourselves to the growth stocks in the S&P 500, we invested in growth stocks in an index that held more stocks? The Vanguard Russell 1000 Growth ETF (NASDAQ: VONG) could be just the ticket. This ETF attempts to track the performance of growth stocks in the Russell 1000 index. Whereas the S&P 500 owns shares of the 500 largest U.S. companies, the Russell 1000 owns shares of the largest 1,000 companies. The Vanguard Russell 1000 Growth ETF's portfolio currently includes 387 stocks. Like the other two ETFs on our list, this Vanguard ETF began trading in September 2010. Since its inception, the fund has generated an average annual return of 16.9%. That makes it the best-performing ETF in the Vanguard family. How long would it take to make $1 million investing $500 per month at that return? Less than 21 years. If you kept socking away money for 30 years, you'd have nearly $4.5 million. Again, there's no way to know for sure whether the Vanguard Russell 1000 Growth ETF will provide such a sky-high return over the long term. I wouldn't count on it. But this Vanguard ETF could still provide a great vehicle for investors to make $1 million or more for retirement. Should you buy stock in Vanguard S&P 500 ETF right now? Before you buy stock in Vanguard S&P 500 ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Vanguard S&P 500 ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Vanguard S&P 500 ETF. The Motley Fool has a disclosure policy. 3 Vanguard ETFs That Can Turn $500 per Month Into Over $1 Million was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Motley Fool CEO Recommends Dividend & Value Plays for a Defensive Stance Today
Key Points The S&P 500 has cruised to a record high and is trading at lofty valuations. The Motley Fool CEO urges investors to take a different approach to investing now. 10 stocks we like better than Enterprise Products Partners › Investors in stock markets have witnessed historic volatility in 2025 so far. After peaking in February, the S&P 500 (SNPINDEX: ^GSPC) index briefly slipped into correction territory in April. Many feared a market crash, but the S&P 500 has instead staged one of its most dramatic V-shaped recoveries since and just hit a record high. The wild ride has left investors wondering whether the stock market is overheated and whether they should invest in stocks now or remain on the sidelines. The fear is warranted. The S&P 500 is currently trading at over 25 times earnings, and U.S. stocks now account for 65% of all stocks worldwide. Those are historically high valuations. Yet, even at these lofty market levels, you can still beat the market in the long term if you know where to look. The Motley Fool CEO and co-founder, Tom Gardner, believes the key to beating the market now lies in looking "where people aren't looking." The type of stocks investors should buy now In a recent interview, Gardner shared his perspective on the current state of the market and how investors should approach investing. While recognizing that the markets are at high valuations, Gardner maintains that there are still hundreds of good stocks you could buy now, but they're probably "not the most well-known, actively followed, most richly valued" stocks. Gardner believes it's time to be "a little more defensive" right now and look for investments "where others aren't looking." I'm saying if you're looking for good returns over the next 3-5 years that beat the market, I think you need to look where others aren't looking now, and you need to look for dividend payers, more value-oriented investing. At least where we are in valuation now. So, where can you look to invest now? Think dividends, defensive, and value stocks. While good dividend stocks can generate a steady stream of passive income even during turbulent times, defensive stocks are typically recession-proof stocks and a great way to reduce your portfolio risk. Value stocks, meanwhile, trade for a price lower than what their fundamentals merit. More often than not, some of the most boring businesses fit two or more of these three stock categories, and there are plenty of such stocks today that could beat the market in the long term. In today's environment, three stocks come to mind. A 6.9%-yielding safe energy dividend stock Enterprise Products Partners (NYSE: EPD) is one of the largest midstream energy companies in the U.S., owning over 50,000 miles of pipeline. It stores, processes, and transports natural gas liquids and other products under long-term contracts in return for a fee. The business is recession-proof and largely immune to the volatility in oil and gas prices. Moreover, 90% of the contracts have escalation clauses to offset the effects of inflation. All those factors combined mean that Enterprise Products can generate steady, predictable cash flows and pay regular, growing dividends. The energy giant has increased its dividend for 26 consecutive years, and the stock yields a hefty 6.9%. With Enterprise Products bringing $6 billion of the $7.6 billion in major capital projects online this year, investors can expect to see steady growth in its cash flows and dividends, regardless of where the economy or stock markets are. A defensive dividend growth bet Brookfield Infrastructure's (NYSE: BIPC)(NYSE: BIP) business is also recession-resilient, as it earns from defensive assets, such as utilities, rail and toll roads, midstream energy, and data centers. Nearly 85% of Brookfield's funds from operations (FFO) are contracted or regulated and indexed to inflation. While that makes its cash flows predictable, regular acquisitions and recycling of old, mature assets drive cash flows higher. Over the past 15 years, Brookfield has grown its FFO per unit by a compound annual growth rate (CAGR) of 15% and its dividend by a 9% CAGR. With the company targeting over 10% FFO growth and 5% to 9% annual dividend growth in the long term, Brookfield Infrastructure is a great stock to own during uncertain times. The corporate shares also yield a good 4%. A beaten-down Dividend King to buy Unlike Enterprise Products and Brookfield Infrastructure, which are defensive stocks, Nucor (NYSE: NUE) is a cyclical stock. However, you'd be surprised to see the kind of total returns it has generated in recent years. Nucor is the largest and most diversified steel producer in North America. While this exposes the company to commodity prices, Nucor has sailed through turbulent times primarily due to two reasons. First, it uses electric arc furnaces in steel mills. They are more flexible, efficient, and cost-effective compared to traditional blast furnaces. Second, its mills use scrap as the key raw material, which Nucor produces internally. Vertical integration, a cost-efficient business model, and a strong balance sheet contribute to Nucor's status as a Dividend King, having increased its dividend for 52 consecutive years. With President Donald Trump imposing hefty tariffs on steel imports, Nucor could be a solid turnaround story. Trading at 30% off all-time highs as of this writing, Nucor is one value plus dividend growth stock you could buy now. Do the experts think Enterprise Products Partners is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Enterprise Products Partners make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,041% vs. just 183% for the S&P — that is beating the market by 858.71%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Neha Chamaria has no position in any of the stocks mentioned. The Motley Fool recommends Brookfield Infrastructure Partners and Enterprise Products Partners. The Motley Fool has a disclosure policy. Motley Fool CEO Recommends Dividend & Value Plays for a Defensive Stance Today was originally published by The Motley Fool Sign in to access your portfolio
